Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone

Clinical Pharmacology and Therapeutics
Mikko NiemiPertti J Neuvonen

Abstract

Trimethoprim is a relatively selective inhibitor of the cytochrome P450 (CYP) 2C8 enzyme in vitro. Rifampin (INN, rifampicin) is a potent inducer of several CYP enzymes, and in vitro studies have suggested that it also induces CYP2C8. Our aims were to investigate possible effects of trimethoprim and rifampin on CYP2C8 activity by use of rosiglitazone, a thiazolidinedione antidiabetic drug metabolized primarily by CYP2C8, as an in vivo probe. Two separate randomized crossover studies with 2 phases were conducted. In study 1, 10 healthy volunteers took 160 mg trimethoprim or placebo orally twice daily for 4 days. On day 3, they ingested a single 4-mg dose of rosiglitazone. In study 2, 10 healthy volunteers took 600 mg rifampin or placebo orally once daily for 5 days. On day 6, they ingested a single 4-mg dose of rosiglitazone. In both studies, plasma rosiglitazone and N -desmethylrosiglitazone concentrations were measured for up to 48 hours. Results In study 1, trimethoprim raised the area under the plasma rosiglitazone concentration-time curve [AUC(0- infinity )] by 37% (range, 16% to 51%; P <.0001) and the peak plasma rosiglitazone concentration (C max ) by 14% (range, -3% to 38%; P =.0014). The elimination half-life (t 1/2 ) o...Continue Reading

Citations

Nov 17, 2012·Expert Opinion on Drug Metabolism & Toxicology·Andreas HolsteinPeter Kovacs
Jan 2, 2016·Pharmacological Reviews·Janne T BackmanPertti J Neuvonen
Jul 27, 2006·Basic & Clinical Pharmacology & Toxicology·Tiina JaakkolaJanne T Backman
Jul 22, 2006·British Journal of Clinical Pharmacology·Rasmus S PedersenKim Brosen
Sep 20, 2006·British Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jan 5, 2006·British Journal of Clinical Pharmacology·Tiina JaakkolaPertti J Neuvonen
Oct 1, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yohei KosugiToshiya Moriwaki
Nov 29, 2014·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Ahmed A AlbassamReginald F Frye
Jun 23, 2015·Clinical Pharmacology in Drug Development·Rene A BraeckmanParesh N Soni
Jan 12, 2017·Drugs in R&D·Maryam BazarganBeverly S Muhlhausler
Jul 20, 2005·Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jan 5, 2007·Clinical Pharmacokinetics·André J Scheen
Jul 12, 2008·Archives of Toxicology·Olavi PelkonenHannu Raunio
Oct 20, 2010·Tropical Medicine & International Health : TM & IH·Rovina RuslamiReinout van Crevel
Jul 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Jan 17, 2012·British Journal of Clinical Pharmacology·Himanshu NaikLachy McLean
Oct 4, 2012·Expert Review of Anti-infective Therapy·Christie Y JeonMeghan A Baker
Aug 22, 2013·Pharmacogenetics and Genomics·Christina L AquilanteTeri E Klein
Jan 20, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Chang-Woo YeoJae-Gook Shin
Sep 24, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Janne T BackmanPertti J Neuvonen
Oct 5, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Aleksi TornioJanne T Backman
Oct 24, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kajsa P Kanebratt, Tommy B Andersson
Jun 24, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Brooke M VandenBrinkJan L Wahlstrom
Nov 6, 2012·Expert Review of Clinical Pharmacology·Janne Hukkanen
Jun 12, 2013·European Journal of Drug Metabolism and Pharmacokinetics·Myung-Jin ChoiSeung-Chun Park
Jun 21, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Oct 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Helena W RodbardStanley S Schwartz
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen
Feb 1, 2018·Chemical Reviews·Tianao Yuan, Nicole S Sampson
Sep 30, 2020·Current Drug Metabolism·Xuan YuChen Cheng
Feb 16, 2008·The American Journal of the Medical Sciences·Anne M BaciewiczTimothy H Self
Nov 21, 2009·The Lancet Infectious Diseases·Kelly E Dooley, Richard E Chaisson
Nov 2, 2021·Expert Opinion on Drug Metabolism & Toxicology·Veronica Di PaoloLuigi Quintieri
Nov 28, 2017·Drug Metabolism and Pharmacokinetics·Kenta HarayaYuichi Sugiyama

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Pharmacology and Therapeutics
Kari T KivistöPertti J Neuvonen
British Journal of Clinical Pharmacology
Tiina JaakkolaPertti J Neuvonen
© 2021 Meta ULC. All rights reserved